Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression

被引:13
作者
Du, Fengkun [1 ]
Li, Yan [1 ,2 ]
Zhang, Wensheng [1 ]
Kale, Shubha P. [1 ]
McFerrin, Harris [1 ]
Davenport, Ian [1 ]
Wang, Guangdi [3 ]
Skripnikova, Elena [1 ]
Li, Xiao-Lin [1 ]
Bowen, Nathan J. [4 ]
McDaniels, Leticia B. [1 ]
Meng, Yuan-Xiang [5 ]
Polk, Paula [6 ]
Liu, Yong-Yu [7 ]
Zhang, Qian-Jin [1 ]
机构
[1] Xavier Univ Louisiana, Dept Biol, 1 Drexel Dr, New Orleans, LA 70125 USA
[2] Hebei Univ, Coll Chem & Environm Sci, Baoding 071002, Hebei Provinec, Peoples R China
[3] Xavier Univ Louisiana, Dept Chem, 1 Drexel Dr, New Orleans, LA 70125 USA
[4] Clark Atlanta Univ, Dept Biol Sci, 23 James P Brawley Dr SW, Atlanta, GA 30314 USA
[5] Morehouse Sch Med, Dept Family Med, 1513 E Cleveland Ave,Bldg 100, East Point, GA 30344 USA
[6] LSUHSC Hlth Sci Ctr Shreveport, Res Core Facil, 1501 Kings Hwy, Shreveport, LA 71103 USA
[7] Univ Louisiana Monroe, Dept Basic Pharmaceut Sci, 700 Univ Ave, Monroe, LA 71209 USA
关键词
Ovarian cancer; Bioinformatics; Prognostic biomarkers; TUMOR-SUPPRESSOR GENE; MYC ONCOGENE; PROGESTERONE-RECEPTOR; ANDROGEN RECEPTORS; C-MYC; CARCINOMA; SURVIVAL; STAGE; IDENTIFICATION; ESTROGEN;
D O I
10.1007/s13277-015-4518-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with advanced epithelial ovarian cancer often experience disease recurrence after standard therapies, a critical factor in determining their five-year survival rate. Recent reports indicated that long-term or short-term survival is associated with varied gene expression of cancer cells. Thus, identification of novel prognostic biomarkers should be considered. Since the mouse genome is similar to the human genome, we explored potential prognostic biomarkers using two groups of mouse ovarian cancer cell lines (group 1: IG-10, IG-10pw, and IG-10pw/agar; group 2: IG-10 clones 2, 3, and 11) which display highly and moderately aggressive phenotypes in vivo. Mice injected with these cell lines have different survival time and rates, capacities of tumor, and ascites formations, reflecting different prognostic potentials. Using an Affymetrix Mouse Genome 430 2.0 Array, a total of 181 genes were differentially expressed (P < 0.01) by at least twofold between two groups of the cell lines. Of the 181 genes, 109 and 72 genes were overexpressed in highly and moderately aggressive cell lines, respectively. Analysis of the 109 and 72 genes using Ingenuity Pathway Analysis (IPA) tool revealed two cancer-related gene networks. One was associated with the highly aggressive cell lines and affiliated with MYC gene, and another was associated with the moderately aggressive cell lines and affiliated with the androgen receptor (AR). Finally, the gene enrichment analysis indicated that the overexpressed 89 genes (out of 109 genes) in highly aggressive cell lines had a function annotation in the David database. The cancer-relevant significant gene ontology (GO) terms included Cell cycle, DNA metabolic process, and Programmed cell death. None of the genes from a set of the 72 genes overexpressed in the moderately aggressive cell lines had a function annotation in the David database. Our results suggested that the overexpressed MYC and 109 gene set represented highly aggressive ovarian cancer potential biomarkers while overexpressed AR and 72 gene set represented moderately aggressive ovarian cancer potential biomarkers. Based on our knowledge, the current study is first time to report the potential biomarkers relevant to different aggressive ovarian cancer. These potential biomarkers provide important information for investigating human ovarian cancer prognosis.
引用
收藏
页码:11147 / 11162
页数:16
相关论文
共 46 条
  • [1] Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site
    Ågren, M
    Kogerman, P
    Kleman, MI
    Wessling, M
    Toftgård, R
    [J]. GENE, 2004, 330 : 101 - 114
  • [2] BASERGA R, 1993, CANCER SURV, V16, P201
  • [3] G2E3 is a dual function ubiquitin ligase required for early embryonic development
    Brooks, William S.
    Helton, E. Scott
    Banerjee, Sami
    Venable, Melanie
    Johnson, Larry
    Schoeb, Trenton R.
    Kesterson, Robert A.
    Crawford, David F.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (32) : 22304 - 22315
  • [4] Cancer of the ovary
    Cannistra, SA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) : 2519 - 2529
  • [5] Cardillo MR, 1998, J EXP CLIN CANC RES, V17, P231
  • [6] Cell cycle genes in ovarian cancer: Steps toward earlier diagnosis and novel therapies
    D'Andrilli, G
    Kumar, C
    Scambia, G
    Giordano, A
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8132 - 8141
  • [7] D'Andrilli Giuseppina, 2008, Open Clin Cancer J, V2, P7, DOI 10.2174/1874189400802010007
  • [8] MYC on the Path to Cancer
    Dang, Chi V.
    [J]. CELL, 2012, 149 (01) : 22 - 35
  • [9] Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation
    de Bruin, A
    Maiti, B
    Jakoi, L
    Timmers, C
    Buerki, R
    Leone, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) : 42041 - 42049
  • [10] MYC oncogene in myeloid neoplasias
    Dolores Delgado, M.
    Albajar, Marta
    Teresa Gomez-Casares, M.
    Batlle, Ana
    Leon, Javier
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (02) : 87 - 94